CBLN1 and glioblastoma: Different lines of evidence indicate that both aberrant activation of the PI3K/Akt survival pathway [56,57] and downregulation of the death mediator Cer [25] play a critical role in the aggressive behavior, apoptosis resistance, and adverse clinical outcome of glioblastomas.